Plant-made immunogens and effective delivery strategies

Expert Review of Vaccines

Volumn 9, Issue 8, 2010, Pages 821-833

  Paul, Matthew ^a   Ma, Julian K C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

adjuvant; molecular pharming; plant made pharmaceuticals; PMP; post translational modification; vaccine; virus like particles; VLP

Indexed keywords

ARABIDOPSIS THALIANA EXTRACT; CHENOPODIUM AMARANTICOLOR EXTRACT; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; DAUCUS CAROTA EXTRACT; HEAT LABILE TOXIN B SUBUNIT; INFLUENZA VACCINE; NICOTIANA BENTHAMIANA EXTRACT; PLANT ANTIGEN; POLIOMYELITIS VACCINE; POTATO EXTRACT; RECOMBINANT ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; ROTAVIRUS VACCINE; SPINACIA OLERACEA EXTRACT; UNCLASSIFIED DRUG; VIGNA UNGUICULATA EXTRACT; WART VIRUS VACCINE; ZEA MAYS EXTRACT; RECOMBINANT VACCINE;

DRUG DELIVERY SYSTEM; FACIAL NERVE PARALYSIS; FEASIBILITY STUDY; GENE EXPRESSION SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TECHNOLOGY; VACCINE PRODUCTION; VIRUS LIKE AGENT; BIOSYNTHESIS; BIOTECHNOLOGY; GENETICS; IMMUNOLOGY; PHARMACEUTICS; PROCEDURES; TRANSGENIC PLANT;

BIOTECHNOLOGY; DRUG DELIVERY SYSTEMS; HUMANS; PLANTS, GENETICALLY MODIFIED; TECHNOLOGY, PHARMACEUTICAL; VACCINES, SYNTHETIC;

EID: 77955236788     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.88     Document Type: Review

References (122)

1. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 430(6996), 242-249 (2004).
2. Dubock A. Learnings from public: private partnerships for GM crops. Presented at: 7th ICABR: International Conference on Public Goods and Public Policy for Agricultural Biotechnology. Ravello, Italy, 29 June-3 July 2003.
3. Dunwell JM. Review: intellectual property aspects of plant transformation. Plant Biotechnol. J. 3(4), 371-384 (2005).
4. Fischer R, Stoger E, Schillberg S, Christou P, Twyman RM. Plant-based production of biopharmaceuticals. Curr. Opin. Plant Biol. 7(2), 152-158 (2004).
5. Twyman RM, Stoger E, Schillberg S, Christou P, Fischer R. Molecular farming in plants: host systems and expression technology. Trends Biotechnol. 21(12), 570-578 (2003).
6. Perlak FJ, Fuchs RL, Dean DA, McPherson SL, Fischhoff DA. Modification of the coding sequence enhances plant expression of insect control protein genes. Proc. Natl Acad. Sci. USA 88(8), 3324-3328 (1991).
7. Rouwendal GJ, Mendes O, Wolbert EJ, Douwe de Boer A. Enhanced expression in tobacco of the gene encoding green fluorescent protein by modification of its codon usage. Plant Mol. Biol. 33(6), 989-999 (1997).
8. Benchabane M, Rivard D, Girard C, Michaud D. Companion protease inhibitors to protect recombinant proteins in transgenic plant extracts. Methods Mol. Biol. 483, 265-273 (2009).
9. Conrad U, Fiedler U. Compartment- specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity. Plant Mol. Biol. 38(1-2), 101-109 (1998).
10. Allen GC, Hall G Jr, Michalowski S et al. High-level transgene expression in plant cells: effects of a strong scaffold attachment region from tobacco. Plant Cell 8(5), 899-913 (1996).
11. van Rooijen GJ, Moloney MM. Plant seed oil-bodies as carriers for foreign proteins. Biotechnology (NY) 13(1), 72-77 (1995).
12. Alvarez ML, Topal E, Martin F, Cardineau GA. Higher accumulation of F1-V fusion recombinant protein in plants after induction of protein body formation. Plant Mol. Biol. 72(1-2), 75-89 (2010).
13. Obregon P, Chargelegue D, Drake PM et al. HIV-1 p24-immunoglobulin fusion molecule: a new strategy for plant-based protein production. Plant Biotechnol. J. 4(2), 195-207 (2006).
14. Marusic C, Vitale A, Pedrazzini E et al. Plant-based strategies aimed at expressing HIV antigens and neutralizing antibodies at high levels. Nef as a case study. Transgenic Res. 18(4), 499-512 (2009).
15. Dorokhov YL, Sheveleva AA, Frolova OY et al. Superexpression of tuberculosis antigens in plant leaves. Tuberculosis (Edinb.) 87(3), 218-224 (2007).
16. Wycoff KL. Secretory IgA antibodies from plants. Curr. Pharm. Des. 11(19), 2429-2437 (2005).
17. D'Aoust MA, Lavoie PO, Couture MM et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol. J. 6(9), 930-940 (2008).
18. McCormick AA, Reddy S, Reinl SJ et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a Phase I clinical study. Proc. Natl Acad. Sci. USA 105(29), 10131-10136 (2008).
19. Jarvis P. Targeting of nucleus-encoded proteins to chloroplasts in plants. New Phytol. 179(2), 257-285 (2008).
20. Brodzik R, Spitsin S, Pogrebnyak N et al. Generation of plant-derived recombinant DTP subunit vaccine. Vaccine 27(28), 3730-3734 (2009).
21. Chebolu S, Daniell H. Chloroplast-derived vaccine antigens and biopharmaceuticals: expression, folding, assembly and functionality. Curr. Top. Microbiol. Immunol. 332, 33-54 (2009).
22. Staub JM, Garcia B, Graves J et al. High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat. Biotechnol. 18(3), 333-338 (2000).
23. Sola RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 24(1), 9-21 (2010).
24. Gomord V, Chamberlain P, Jefferis R, Faye L. Biopharmaceutical production in plants: problems, solutions and opportunities. Trends Biotechnol. 23(11), 559-565 (2005).
25. Jin C, Altmann F, Strasser R et al. A plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits. Glycobiology 18(3), 235-241 (2008).
26. Ma JK, Drake PM, Chargelegue D, Obregon P, Prada A. Antibody processing and engineering in plants, and new strategies for vaccine production. Vaccine 23(15), 1814-1818 (2005).
27. Schahs M, Strasser R, Stadlmann J et al. Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol. J. 5(5), 657-663 (2007).
28. Strasser R, Stadlmann J, Schahs M et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6(4), 392-402 (2008).
29. Shields RL, Lai J, Keck R et al. Lack of fucose on human IgGj N-linked oligosaccharide improves binding to human Fcg RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277(30), 26733-26740 (2002).
30. Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc. Natl Acad. Sci. USA 104(20), 8433-8437 (2007).
31. Strasser R, Castilho A, Stadlmann J et al. Improved virus neutralization by plant- produced anti-HIV antibodies with a homogeneous (31,4-galactosylated N-glycan profile. J. Biol. Chem. 284(31), 20479-20485 (2009).
32. Rajala RV, Datla RS, Moyana TN et al. N-myristoyltransferase. Mol. Cell Biochem. 204(1-2), 135-155 (2000).
33. Naik RS, Branch OH, Woods AS et al. Glycosylphosphatidylinositol anchors of Plasmodium falciparum: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. J. Exp. Med. 192(11), 1563-1576 (2000).
34. Crowell DN, Huizinga DH. Protein isoprenylation: the fat of the matter. Trends Plant Sci. 14(3), 163-170 (2009).
35. Takos AM, Dry IB, Soole KL. Glycosyl- phosphatidylinositol-anchor addition signals are processed in Nicotiana tabacum. Plant J. 21(1), 43-52 (2000).
36. Traverso JA, Meinnel T, Giglione C. Expanded impact of protein N-myristoylation in plants. Plant Signal. Behav. 3(7), 501-502 (2008).
37. Marusic C, Nuttall J, Buriani G et al. Expression, intracellular targeting and purification of HIV Nef variants in tobacco cells. BMC Biotechnol. 7, 12 (2007).
38. Farran I, McCarthy-Suarez I, Rio-Manterola F et al. The vaccine adjuvant extra domain A from fibronectin retains its proinflammatory properties when expressed in tobacco chloroplasts. Planta 231(4), 977-990 (2010).
39. Medrano G, Dolan MC, Stephens NT et al. Efficient plant-based production of chicken interleukin-12 yields a strong immunostimulatory cytokine. J. Interferon Cytokine Res. 30(3), 143-154 (2010).
40. Chikwamba R, Cunnick J, Hathaway D et al. A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Res. 11(5), 479-493 (2002).
41. Tacket CO, Mason HS, Losonsky G et al. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med. 4(5), 607-609 (1998).
42. Yuki Y, Tokuhara D, Nochi T et al. Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity. Vaccine 27(43), 5982-5988 (2009).
43. Matsumoto Y, Suzuki S, Nozoye T et al. Oral immunogenicity and protective efficacy in mice of transgenic rice plants producing a vaccine candidate antigen (As16) of Ascaris suum fused with cholera toxin B subunit. Transgenic Res. 18(2), 185-192 (2009).
44. Matoba N, Kajiura H, Cherni I et al. Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR. Plant Biotechnol. J. 7(2), 129-145 (2009).
45. Nochi T, Takagi H, Yuki Y et al. Rice- based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc. Natl Acad. Sci. USA 104(26), 10986-10991 (2007).
46. Millar DG, Hirst TR, Snider DP. Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin. Infect. Immun. 69(5), 3476-3482 (2001).
47. Tregoning JS, Clare S, Bowe F et al. Protection against tetanus toxin using a plant-based vaccine. Eur. J. Immunol. 35(4), 1320-1326 (2005).
48. Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine 22(31-32), 4385-4389 (2004).
49. Haan L, Verweij WR, Holtrop M et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19(20-22), 2898-2907 (2001).
50. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004).
51. Sun JB, Czerkinsky C, Holmgren J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand. J. Immunol. 71(1), 1-11 (2010).
52. Chargelegue D, Drake PM, Obregon P et al. Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants. Infect. Immun. 73(9), 5915-5922 (2005).
53. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Adv. Exp. Med. Biol. 655, 145-158 (2009).
54. Kapusta J, Modelska A, Figlerowicz M et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 13(13), 1796-1799 (1999).
55. Santi L, Batchelor L, Huang Z et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 26(15), 1846-1854 (2008).
56. Tacket CO, Mason HS, Losonsky G et al. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 182(1), 302-305 (2000).
57. Fernandez-San Millan A, Ortigosa SM, Hervas-Stubbs S et al. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol. J. 6(5), 427-441 (2008).
58. Yusibov V, Mett V, Davidson C et al. Peptide-based candidate vaccine against respiratory syncytial virus. Vaccine 23(17-18), 2261-2265 (2005).
59. Gonzalez MJ, Plummer EM, Rae CS, Manchester M. Interaction of cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivo. PLoS One 4(11), e7981 (2009).
60. Kumar S, Ochoa W, Singh P et al. Tomato bushy stunt virus (TBSV), a versatile platform for polyvalent display of antigenic epitopes and vaccine design. Virology 388(1), 185-190 (2009).
61. Lico C, Mancini C, Italiani P et al. Plant-produced potato virus X chimeric particles displaying an influenza virus- derived peptide activate specific CD8+ T cells in mice. Vaccine 27(37), 5069-5076 (2009).
62. Pogue GP, Lindbo JA, Garger SJ, Fitzmaurice WP. Making an ally from an enemy: plant virology and the new agriculture. Annu. Rev. Phytopathol. 40, 45-74 (2002).
63. Smith ML, Lindbo JA, Dillard-Telm S et al. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology 348(2), 475-488 (2006).
64. Nuzzaci M, Vitti A, Condelli V et al. In vitro stability of cucumber mosaic virus nanoparticles carrying a hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine. J. Virol. Methods 165(2), 211-215 (2010).
65. Bachmann MF, Zinkernagel RM, Oxenius A. Immune responses in the absence of costimulation: viruses know the trick. J. Immunol. 161(11), 5791-5794 (1998).
66. Kapusta J, Pniewski T, Wojciechowicz J, Bociag P, Plucienniczak A. Nanogram doses of alum-adjuvanted HBs antigen induce humoral immune response in mice when orally administered. Arch. Immunol. Ther. Exp. (Warsz) 58(2), 143-151 (2010).
67. Thanavala Y, Mahoney M, Pal S et al. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc. Natl Acad. Sci. USA 102(9), 3378-3382 (2005).
68. Saunders K, Sainsbury F, Lomonossoff GP. Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants. Virology 393(2), 329-337 (2009).
69. Rae CS, Khor IW, Wang Q et al. Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology 343 (2), 224-235 (2005).
70. Thanavala Y, Yang YF, Lyons P, Mason HS, Arntzen C. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc. Natl Acad. Sci. USA 92(8), 3358-3361 (1995).
71. Wen SX, Teel LD, Judge NA, O'Brien AD. A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc. Natl Acad. Sci. USA 103(18), 7082-7087 (2006).
72. Wang L, Webster DE, Campbell AE et al. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants. Int. J. Parasitol. 38 (1), 103-110 (2008).
73. O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines 2(2), 269-283 (2003).
74. McSorley SJ, Ehst BD, Yu Y, Gewirtz AT. Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J. Immunol. 169(7), 3914-3919 (2002).
75. Yusibov V, Hooper DC, Spitsin SV et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20(25-26), 3155-3164 (2002).
76. Mestecky J, Russell MW, Elson CO. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J. Immunol. 179(9), 5633-5638 (2007).
77. Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-p-secreting regulatory cells. Microbes Infect. 3(11), 947-954 (2001).
78. van den Berg H, Greuter M, Kraal G, den Haan JM. Different mechanisms regulate CD4+ T cell independent induction of oral and nasal tolerance of CD8 + T cells. Immunobiology 215(2), 163-171 (2010).
79. Castanon S, Martin-Alonso JM, Marin MS et al. The effect of the promoter on expression of VP60 gene from rabbit hemorrhagic disease virus in potato plants. Plant Sci. 162(1), 87-95 (2002).
80. Walmsley AM, Alvarez ML, Jin Y et al. Expression of the B subunit of Escherichia coli heat-labile enterotoxin as a fusion protein in transgenic tomato. Plant Cell Rep. 21(10), 1020-1026 (2003).
81. Rigano MM, Alvarez ML, Pinkhasov J et al. Production of a fusion protein consisting of the enterotoxigenic Escherichia coli heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Rep. 22(7), 502-508 (2004).
82. Rademacher T, Sack M, Arcalis E et al. Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol. J. 6(2), 189-201 (2008).
83. Kiyono H, FukuyaSchmidt M.A. NALT-versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol, 4(9), 699-710 (2004).
84. Tregoning JS, Nixon P, Kuroda H et al. Expression of tetanus toxin fragment C in tobacco chloroplasts. Nucleic Acids Res. 31(4), 1174-1179 (2003).
85. Dietrich G, Griot-Wenk M, Metcalfe IC, Lang AB, Viret JF. Experience with registered mucosal vaccines. Vaccine 21(7-8), 678-683 (2003).
86. Unger WW, Jansen W, Wolvers DA et al. Nasal tolerance induces antigen-specific CD4+CD25-regulatory T cells that can transfer their regulatory capacity to naive CD4+ T cells. Int. Immunol. 15(6), 731-739 (2003).
87. Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines 9(3), 299-307 (2010).
88. Chen Q, Morris G, Lai H. cGMP processing of a plant-produced human vaccine candidate for sexually transmitted infections. Presented at: 2009ASABE Annual International Meeting. NV, USA, June 21-24 (2009).
89. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol, 6(2), 148-158 (2006).
90. Burton DR. Antibodies, viruses and vaccines. Nat. Rev. Immunol, 2(9), 706-713 (2002).
91. Arlen PA, Singleton M, Adamovicz JJ et al. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect. Immun. 76(8), 3640-3650 (2008).
92. Webster DE, Cooney ML, Huang Z et al. Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J. Virol. 76(15), 7910-7912 (2002).
93. Webster DE, Smith SD, Pickering RJ et al. Measles virus hemagglutinin protein expressed in transgenic lettuce induces neutralising antibodies in mice following mucosal vaccination. Vaccine 24(17), 3538-3544 (2006).
94. Cunha T, Aires-Barros R. Large-scale extraction of proteins. Mol. Biotechnol. 20(1), 29-40 (2002).
95. Kim TG, Kim BG, Kim MY et al. Expression and immunogenicity of enterotoxigenic Escherichia coli heat-labile toxin B subunit in transgenic rice callus. Mol. Biotechnol. 44(1), 14-21 (2010).
96. Modelska A, Dietzschold B, Sleysh N et al. Immunization against rabies with plant-derived antigen. Proc. Natl Acad. Sci. USA 95(5), 2481-2485 (1998).
97. Loza-Rubio E, Rojas E, Gomez L, Olivera MT, Gomez-Lim MA. Development of an edible rabies vaccine in maize using the Vnukovo strain. Dev. Biol. (Basel) 131, 477-482 (2008).
98. Nochi T, Yuki Y, Katakai Y et al. A rice-based oral cholera vaccine induces macaque-specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity. J. Immunol. 183(10), 6538-6544 (2009).
99. Chichester JA, Musiychuk K, Farrance CE et al. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague. Vaccine 27(25-26), 3471-3474 (2009).
100. Golovkin M, Spitsin S, Andrianov V et al. Smallpox subunit vaccine produced in Planta confers protection in mice. Proc. Natl Acad. Sci. USA 104(16), 6864-6869 (2007).
101. Portocarrero C, Markley K, Koprowski H, Spitsin S, Golovkin M. Immunogenic properties of plant-derived recombinant smallpox vaccine candidate pB5. Vaccine 26(43), 5535-5540 (2008).
102. Pickering RJ, Smith SD, Strugnell RA, Wesselingh SL, Webster DE. Crude saponins improve the immune response to an oral plant-made measles vaccine. Vaccine 24(2), 144-150 (2006).
103. Chia MY, Hsiao SH, Chan HT et al. Immunogenicity of recombinant GP5 protein of porcine reproductive and respiratory syndrome virus expressed in tobacco plant. Vet. Immunol. Immunopathol. 135(3-4), 234-242 (2010).
104. Wigdorovitz A, Carrillo C, Dus Santos MJ et al. Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 255(2), 347-353 (1999).
105. Wu L, Jiang L, Zhou Z et al. Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector. Vaccine 21(27-30), 4390-4398 (2003).
106. Wu H, Scissum-Gunn K, Singh NK, Giambrone JJ. Toward the development of a plant-based vaccine against reovirus. Avian Dis. 53(3), 376-381 (2009).
107. Youm JW, Jeon JH, Kim H et al. High-level expression of a human beta-site APP cleaving enzyme in transgenic tobacco chloroplasts and its immunogenicity in mice. Transgenic Res. 10.1007/s11248-010- 9383-9388 (2010) (Epub ahead of print).
108. Davoodi-Semiromi A, Schreiber M, Nalapalli S et al. Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnol. J. 8(2), 223-242 (2010).
109. Brennan FR, Bellaby T, Helliwell SM et al. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice. J. Virol. 73(2), 930-938 (1999).
110. Zhang H, Liu M, Li Y et al. Oral immunogenicity and protective efficacy in mice of a carrot-derived vaccine candidate expressing UreB subunit against Helicobacter pylori. Protein Expr. Purif. 69(2), 127-131 (2010).
111. Wang Y, Deng H, Zhang X et al. Generation and immunogenicity of Japanese encephalitis virus envelope protein expressed in transgenic rice. Biochem. Biophys. Res. Commun. 380(2), 292-297 (2009).
112. Suzuki K, Kaminuma O, Yang L et al. Development of transgenic rice expressing mite antigen for a new concept of immunotherapy. Int. Arch. Allergy Immunol. 149 (Suppl. 1), 21-24 (2009).
113. Warzecha H, Mason HS, Lane C et al. Oral immunogenicity of human papillomavirus- like particles expressed in potato. J. Virol. 77(16), 8702-8711 (2003).
114. Webster DE, Wang L, Mulcair M et al. Production and characterization of an orally immunogenic Plasmodium antigen in plants using a virus-based expression system. Plant Biotechnol. J. 7(9), 846-855 (2009).
115. Durrani Z, McInerney TL, McLain L et al. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J. Immunol. Methods 220(1-2), 93-103 (1998).
116. Zhang Y, Li J, Pu H et al. Development of tobacco necrosis virus A as a vector for efficient and stable expression of FMDV VP1 peptides. Plant Biotechnol. J. 8(4), 506-523 (2010).
117. Marusic C, Rizza P, Lattanzi L et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J. Virol. 75(18), 8434-8439 (2001).
118. Dow Agrosciences. First Licence (2008) www.dowagro.com/animalhealth/ resources/firstlic.htm
119. Bayer Innovation. Bayer starts clinical Phase I study with personalized vaccine from tobacco plants (2010) www.press.bayer.com/baynews/baynews . nsf/id/0AA54C60C9F567D2C12576B900 38E7C4?Open
120. Phase 1 Norwalk Vaccine Study 806962?term=NCT00806962&rank=1
121. Norwalk Vaccine Study 73284?term=NCT00973284&rank=1
122. Pharma Planta Consortium (EU framework 5 project) (2008) www.pharma-planta.org